Human induced pluripotent stem cells derived hepatocytes: rising promise for disease modeling, drug development and cell therapy

Abstract

Recent advances in the study of human hepatocytes derived from induced pluripotent stem cells (iPSC) represent new promises for liver disease study and drug discovery. Human hepatocytes or hepatocyte-like cells differentiated from iPSC recapitulate many functional properties of primary human hepatocytes and have been demonstrated as a powerful and efficient tool to model human liver metabolic diseases and facilitate drug development process. In this review, we summarize the recent progress in this field and discuss the future perspective of the application of human iPSC derived hepatocytes.

Keywords

induced pluripotent stem cells / hepatocytes / disease modeling / drug development / cell therapy

References

[1] Asgari, S., Pournasr, B., Salekdeh, G.H., Ghodsizadeh, A., Ott, M., and Baharvand, H. (2010). Induced pluripotent stem cells: a new era for hepatology. J Hepatol 53, 738-751 .10.1016/j.jhep.2010.05.009
[2] Baxter, M.A., Rowe, C., Alder, J., Harrison, S., Hanley, K.P., Park, B.K., Kitteringham, N.R., Goldring, C.E., and Hanley, N.A. (2010). Generating hepatic cell lineages from pluripotent stem cells for drug toxicity screening. Stem Cell Res 5, 4-22 .10.1016/j.scr.2010.02.002
[3] Busletta, C., Novo, E., and Parola, M. (2011). Human-induced pluripotent stem cells as a source of hepatocyte-like cells: new kids on the block. Hepatol Int . 2011July23. doi: 10.1007/s12072-011- 9300-0. [Published online]10.1007/s12072-011- 9300-0. 10.1007/s12072-011- 9300-0. [Published online]
[4] Chen, Y.F., Tseng, C.Y., Wang, H.W., Kuo, H.C., Yang, V.W., and Lee, O.K. (2011). Rapid generation of mature hepatocyte-like cells from human induced pluripotent stem cells by an efficient three-step protocol. Hepatology. 2011Nov16. doi: 10.1002/hep. 24790. [Epub ahead of print]10.1002/hep. 2479010.1002/hep
[5] Chistiakov, D.A., and Chistiakov, P.A. (2012). Strategies to produce hepatocytes and hepatocyte-like cells from pluripotent stem cells. Hepatol Res 42, 111-119 .10.1111/j.1872-034X.2011.00896.x
[6] Chun, Y.S., Chaudhari, P., and Jang, Y.Y. (2010). Applications of patient-specific induced pluripotent stem cells; focused on disease modeling, drug screening and therapeutic potentials for liver disease. Int J Biol Sci 6, 796-805 .10.7150/ijbs.6.796
[7] Dhawan, A., Puppi, J., Hughes, R.D., and Mitry, R.R. (2010). Human hepatocyte transplantation: current experience and future challenges. Nat Rev Gastroenterol Hepatol 7, 288-298 .10.1038/nrgastro.2010.44
[8] Greenbaum, L.E. (2010). From skin cells to hepatocytes: advances in application of iPS cell technology. J Clin Invest 120, 3102-3105 .10.1172/JCI44422
[9] Hewitt, N.J., Lechón, M.J., Houston, J.B., Hallifax, D., Brown, H.S., Maurel, P., Kenna, J.G., Gustavsson, L., Lohmann, C., Skonberg, C., . (2007). Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies. Drug Metab Rev 39, 159-234 .10.1080/03602530601093489
[10] Katoh, M., Tateno, C., Yoshizato, K., and Yokoi, T. (2008). Chimeric mice with humanized liver. Toxicology 246, 9-17 .10.1016/j.tox.2007.11.012
[11] Liu, G.H., Sancho-Martinez, I., and Izpisua Belmonte, J.C. (2012). Cut and Paste: restoring cellular function by gene correction. Cell Res 22, 283-284 .10.1038/cr.2011.192
[12] Liu, G.H., Suzuki, K., Qu, J., Sancho-Martinez, I., Yi, F., Li, M., Kumar, S., Nivet, E., Kim, J., Soligalla, R.D., . (2011). Targeted gene correction of laminopathy-associated LMNA mutations in patient-specific iPSCs. Cell Stem Cell 8, 688-694 .10.1016/j.stem.2011.04.019
[13] Liu, H., Ye, Z., Kim, Y., Sharkis, S., and Jang, Y.Y. (2010). Generation of endoderm-derived human induced pluripotent stem cells from primary hepatocytes. Hepatology 51, 1810-1819 .10.1002/hep.23626
[14] Lorenzini, S., Gitto, S., Grandini, E., Andreone, P., and Bernardi, M. (2008). Stem cells for end stage liver disease: how far have we got? World J Gastroenterol 14, 4593-4599 .10.3748/wjg.14.4593
[15] Rashid, S.T., Corbineau, S., Hannan, N., Marciniak, S.J., Miranda, E., Alexander, G., Huang-Doran, I., Griffin, J., Ahrlund-Richter, L., Skepper, J., . (2010). Modeling inherited metabolic disorders of the liver using human induced pluripotent stem cells. J Clin Invest 120, 3127-3136 .10.1172/JCI43122
[16] Robinton, D.A., and Daley, G.Q. (2012). The promise of induced pluripotent stem cells in research and therapy. Nature 481, 295-305 .10.1038/nature10761
[17] Rubin, L.L. (2008). Stem cells and drug discovery: the beginning of a new era? Cell 132, 549-552 .10.1016/j.cell.2008.02.010
[18] Schwartz, R.E., Trehan, K., Andrus, L., Sheahan, T.P., Ploss, A., Duncan, S.A., Rice, C.M., and Bhatia, S.N. (2012). Modeling hepatitis C virus infection using human induced pluripotent stem cells. Proc Natl Acad Sci U S A 109, 2544-2548 .10.1073/pnas.1121400109
[19] Si-Tayeb, K., Lemaigre, F.P., and Duncan, S.A. (2010a). Organogenesis and development of the liver. Dev Cell 18, 175-189 .10.1016/j.devcel.2010.01.011
[20] Si-Tayeb, K., Noto, F.K., Nagaoka, M., Li, J., Battle, M.A., Duris, C., North, P.E., Dalton, S., and Duncan, S.A. (2010b). Highly efficient generation of human hepatocyte-like cells from induced pluripotent stem cells. Hepatology 51, 297-305 .10.1002/hep.23354
[21] Song, Z., Cai, J., Liu, Y., Zhao, D., Yong, J., Duo, S., Song, X., Guo, Y., Zhao, Y., Qin, H., . (2009). Efficient generation of hepatocyte-like cells from human induced pluripotent stem cells. Cell Res 19, 1233-1242 .10.1038/cr.2009.107
[22] Sullivan, G.J., Hay, D.C., Park, I.H., Fletcher, J., Hannoun, Z., Payne, C.M., Dalgetty, D., Black, J.R., Ross, J.A., Samuel, K., . (2010). Generation of functional human hepatic endoderm from human induced pluripotent stem cells. Hepatology 51, 329-335 .10.1002/hep.23335
[23] Takahashi, K., and Yamanaka, S. (2006). Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126, 663-676 .10.1016/j.cell.2006.07.024
[24] Yoshizato, K., and Tateno, C. (2009). In vivo modeling of human liver for pharmacological study using humanized mouse. Expert Opin Drug Metab Toxicol 5, 1435-1446 .10.1517/17425250903216664
[25] Yusa, K., Rashid, S.T., Strick-Marchand, H., Varela, I., Liu, P.Q., Paschon, D.E., Miranda, E., Ordó?ez, A., Hannan, N.R., Rouhani, F.J., . (2011). Targeted gene correction of α1-antitrypsin deficiency in induced pluripotent stem cells. Nature 478, 391-394 .10.1038/nature10424
[26] Zaret, K.S., and Grompe, M. (2008). Generation and regeneration of cells of the liver and pancreas. Science 322, 1490-1494 .10.1126/science.1161431
[27] Zhang, S., Chen, S., Li, W., Guo, X., Zhao, P., Xu, J., Chen, Y., Pan, Q., Liu, X., Zychlinski, D., . (2011). Rescue of ATP7B function in hepatocyte-like cells from Wilson’s disease induced pluripotent stem cells using gene therapy or the chaperone drug curcumin. Hum Mol Genet 20, 3176-3187 .10.1093/hmg/ddr223
[28] Zhang, W., Ding, Z., and Liu, G.H. (2012). Evolution of iPSC disease models. Protein Cell 3, 1-4 .10.1007/s13238-012-2005-x